This ligand-binding induces receptor heterodimerization with ERBB2, causing the activation of the PI3K and MAPK pathways, which results in increased cell proliferation/migration and resistance to apoptosis in cancer [100,101,102,103]. Here, ERBB2 is linked to cancer.